Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$117.5M+42.0% | -$108.12M+39.6% | -$162.25M-69.3% | -$171.9M-76.2% | -$202.49M-122% | ||
| $19.67M+1.8% | $19.48M+50.4% | $21.04M+192% | $23.85M+166% | $19.33M+162% | ||
| $22.22M-38.4% | $23.76M-22.8% | $25.24M+38.3% | $26.16M+58.3% | $36.06M+124% | ||
| -$4.6M-997% | —— | —— | —— | -$419K— | ||
| $0+100% | —— | —— | —— | -$4.5M— | ||
| $2.07M-43.9% | —— | -$5.89M-289% | -$4.84M-260% | $3.69M+216% | ||
| -$18.45M+30.6% | —— | -$8.03M— | —— | -$26.59M-41.0% | ||
| -$14.75M-205% | $0-100% | -$3.53M-191% | -$25.41M— | -$4.84M-565% | ||
| -$1.67M+65.3% | -$2.9M+83.0% | —— | -$4.27M-172% | -$4.82M-961% | ||
| -$2.25M+77.0% | -$6.76M-19.3% | -$6.63M— | -$13.62M-7.8% | -$9.76M+28.5% | ||
| -$81.1M+38.5% | -$46.07M+60.1% | -$117.36M-98.2% | -$76.42M+7.1% | -$131.96M-29.0% | ||
| $258K-85.9% | $1.24M-4.2% | $243K-94.7% | $3.15M+166% | $1.83M-72.5% | ||
| $0-100% | $0— | $2.31M— | $500K— | $1M— | ||
| $0+100% | —— | —— | —— | -$4.44M— | ||
| $80K— | —— | —— | $2.16M-28.1% | $0— | ||
| -$338K+95.4% | -$1.24M-100% | -$2.55M+44.1% | -$5.81M-38.9% | -$7.27M-9.3% | ||
| $2.21M+7.9% | $2.17M+3.1% | $2.13M-7.0% | $2.08M+7,915% | $2.05M+7,773% | ||
| $0-100% | $133.38M+1,109% | $254.46M+1,400% | $100M-61.8% | $41.02M+277% | ||
| -$3.47M-109% | $132.01M+1,141% | $251.34M+1,427% | $97.66M-62.9% | $40.53M+192% | ||
| -$3.83M-179% | $2.09M+160% | $1.87M+364% | $9.26M+7,943% | $4.83M+2,307% | ||
| -$88.74M+5.5% | $86.78M-48.1% | $133.3M— | $24.69M-86.0% | -$93.87M+1.5% | ||
| $0+100% | —— | —— | —— | -$4.5M— | ||
| $730K+21.9% | —— | -$4.06M-811% | -$754K+60.4% | $599K+319% | ||
| -$4.65M+19.2% | -$3.86M+13.4% | -$5.22M-10.9% | -$5.15M-96.2% | -$5.76M-51.8% | ||
| -$18.45M+30.6% | —— | -$8.03M— | —— | -$26.59M-41.0% | ||
| -$14.75M-205% | $0-100% | -$3.53M-191% | -$25.41M— | -$4.84M-565% | ||
| $0+100% | -$20.26M-273% | $0— | -$2.47M— | -$27.13M— | ||
| -$1.67M+65.3% | -$2.9M+83.0% | —— | -$4.27M-172% | -$4.82M-961% | ||
| $0-100% | —— | —— | —— | $5.96M+5,415% | ||
| $80K— | —— | —— | $2.16M-28.1% | $0— | ||
| $0+100% | —— | —— | —— | -$4.44M— | ||
| -$1.26M-181% | —— | —— | —— | $1.55M— | ||
| $2.21M+7.9% | $2.17M+3.1% | $2.13M-7.0% | $2.08M+7,915% | $2.05M+7,773% | ||
| $0-100% | -$29K-114% | —— | —— | $1.15M+1,333% | ||
| -$2.25M+77.0% | -$6.76M-19.3% | -$6.63M— | -$13.62M-7.8% | -$9.76M+28.5% | ||
| $1.92M— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $5.24M-14.5% | $5.23M-4.2% | $5.26M-5.7% | $5.63M+81.3% | $6.13M+148% | ||
| $0-100% | —— | —— | —— | $4.44M— | ||
| -$81.36M+39.2% | -$47.32M+59.5% | -$117.6M-84.4% | -$79.57M+4.6% | -$133.79M-22.8% | ||
| -$81.36M+39.2% | -$47.32M+59.5% | -$117.6M-84.4% | -$79.57M+4.6% | -$133.79M-22.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.